On April 28, 2020, ORIC Pharmaceuticals, a South San Francisco-based clinical-stage oncology company, announced the closing of its initial public offering of 8,625,000 shares of its common stock, which includes the exercise in full of the underwriters’ option to purchase 1,125,000 additional shares of its common stock, at a price to the public of $16.00 per share. The shares began trading on the Nasdaq Global Select Market on April 24, 2020 under the symbol “ORIC.” Wilson Sonsini Goodrich & Rosati advised ORIC Pharmaceuticals in the offering.

The gross proceeds from the offering were $138.0 million, before deducting underwriting discounts and commissions, and estimated offering expenses. J.P Morgan, Citigroup, Jefferies and Guggenheim Securities acted as joint book-running managers for the offering.

ORIC Pharmaceuticals is a clinical-stage oncology company dedicated to improving patients’ lives by Overcoming Resistance In Cancer through its development of small-molecule drugs for treatment-resistant cancers. ORIC’s lead product candidate, ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. ORIC’s second product candidate, ORIC-533, is an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens.  Beyond these two product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California.

The Wilson Sonsini team advising ORIC Pharmaceuticals includes the following attorneys:

Corporate
Kenneth Clark, Partner
Tony Jeffries, Partner
Jennifer Knapp, Partner
Melissa Rick, Partner
Amanda Urquiza, Associate
Benjamin Capps, Associate
Alex Weber, Associate

Patents and Innovations
Michael Hostetler, Partner
Deborah Smith, Associate

Regulatory
David Hoffmeister, Partner
Eva Yin, Associate

Privacy and Cybersecurity
Matt Staples, Partner
Haley Bavasi, Associate

Fintech
Amy Caiazza, Partner

Tax
Myra Sutanto Shen, Partner
Derek Wallace, Of Counsel

Securities Litigation
Nicki Locker, Partner

Please see the company’s press release for more information.